These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Molecular pharmacology of the ovine melatonin receptor: comparison with recombinant human MT1 and MT2 receptors. Mailliet F; Audinot V; Malpaux B; Bonnaud A; Delagrange P; Migaud M; Barrett P; Viaud-Massuard MC; Lesieur D; Lefoulon F; Renard P; Boutin JA Biochem Pharmacol; 2004 Feb; 67(4):667-77. PubMed ID: 14757166 [TBL] [Abstract][Full Text] [Related]
6. High-throughput screening assay for new ligands at human melatonin receptors. Yan JH; Su HR; Boutin JA; Renard MP; Wang MW Acta Pharmacol Sin; 2008 Dec; 29(12):1515-21. PubMed ID: 19026172 [TBL] [Abstract][Full Text] [Related]
7. New melatonin (MT1/MT2) ligands: design and synthesis of (8,9-dihydro-7H-furo[3,2-f]chromen-1-yl) derivatives. Landagaray E; Ettaoussi M; Leclerc V; Traoré B; Perez V; Nosjean O; Boutin JA; Caignard DH; Delagrange P; Berthelot P; Yous S Bioorg Med Chem; 2014 Feb; 22(3):986-96. PubMed ID: 24417958 [TBL] [Abstract][Full Text] [Related]
10. Molecular cloning and pharmacological characterization of rat melatonin MT1 and MT2 receptors. Audinot V; Bonnaud A; Grandcolas L; Rodriguez M; Nagel N; Galizzi JP; Balik A; Messager S; Hazlerigg DG; Barrett P; Delagrange P; Boutin JA Biochem Pharmacol; 2008 May; 75(10):2007-19. PubMed ID: 18384758 [TBL] [Abstract][Full Text] [Related]
11. Synthesis and functional characterization of substituted isoquinolinones as MT2-selective melatoninergic ligands. Hu Y; Chan KH; He X; Ho MK; Wong YH PLoS One; 2014; 9(12):e113638. PubMed ID: 25479338 [TBL] [Abstract][Full Text] [Related]
12. Synthesis, NMR conformational analysis and pharmacological evaluation of 7,7a,13,14-tetrahydro-6H-cyclobuta[b]pyrimido[1,2-a:3,4-a']diindole analogues as melatonin receptor ligands. Attia MI; Güclü D; Hertlein B; Julius J; Witt-Enderby PA; Zlotos DP Org Biomol Chem; 2007 Jul; 5(13):2129-37. PubMed ID: 17581657 [TBL] [Abstract][Full Text] [Related]
13. Tricyclic alkylamides as melatonin receptor ligands with antagonist or inverse agonist activity. Lucini V; Pannacci M; Scaglione F; Fraschini F; Rivara S; Mor M; Bordi F; Plazzi PV; Spadoni G; Bedini A; Piersanti G; Diamantini G; Tarzia G J Med Chem; 2004 Aug; 47(17):4202-12. PubMed ID: 15293992 [TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, and pharmacological effects of structurally simple ligands for MT(1) and MT(2) melatonin receptors. Carocci A; Catalano A; Lovece A; Lentini G; Duranti A; Lucini V; Pannacci M; Scaglione F; Franchini C Bioorg Med Chem; 2010 Sep; 18(17):6496-511. PubMed ID: 20674373 [TBL] [Abstract][Full Text] [Related]
15. Melatonergic ligands: Design, synthesis and pharmacological evaluation of novel series of naphthofuranic derivatives. Landagaray E; Ettaoussi M; Duroux R; Boutin JA; Caignard DH; Delagrange P; Melnyk P; Berthelot P; Yous S Eur J Med Chem; 2016 Feb; 109():360-70. PubMed ID: 26820449 [TBL] [Abstract][Full Text] [Related]
16. The end of a myth: cloning and characterization of the ovine melatonin MT(2) receptor. Cogé F; Guenin SP; Fery I; Migaud M; Devavry S; Slugocki C; Legros C; Ouvry C; Cohen W; Renault N; Nosjean O; Malpaux B; Delagrange P; Boutin JA Br J Pharmacol; 2009 Nov; 158(5):1248-62. PubMed ID: 19814723 [TBL] [Abstract][Full Text] [Related]
17. Preparation and pharmacological evaluation of a novel series of 2-(phenylthio)benzo[b]thiophenes as selective MT2 receptor ligands. Mésangeau C; Fraise M; Delagrange P; Caignard DH; Boutin JA; Berthelot P; Yous S Eur J Med Chem; 2011 May; 46(5):1835-40. PubMed ID: 21392858 [TBL] [Abstract][Full Text] [Related]